Astellas' Fezolinetant Reduces Frequency and Severity of VMS

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity...

Related Keywords

Tokyo , Japan , Netherlands , Amsterdam , Noord Holland , Turkey , Canada , Rossella Nappi , Naoki Okamura , San Matteo Foundation , Head Of Biopharma Development , Health Qual Life Outcomes , European Society Of Gynecology , Astellas Pharma Inc , Elsevier , University Of Pavia , Research Center , Prnewswire Astellas Pharma Inc , European Society , Full Professor , Reproductive Medicine , Gynecological Endocrinology , Menopause Unit , Imatteo Foundation , Vice President , Biopharma Development , Short Form , Area Approach , Equal Life , Clin Endocrinol , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Diversity , Quity Amp Inclusion , Clinical Trials Amp Medical Discoveries , Women ,